Document jyX2bjLOMxaNznvgoqj16kabR

AR226-1394 CS-357S KCV I E. I. du Pont de N emours & Company EHucatsoknealRlnooLaaoInb, doNurIWeaswtItIHroaWirraMyklT,1fMDDoreedlTaicowixnaiecroel1o9g7y11 CENTRAL RESEARCH ANO DEVELOPMENT DEPARTMENT cc : C. F. Reinhardt, CR&D, Haskell R. E. Staples G. L. Kennedy B. W. Karrh, M.D., ERD, N-11400 c - <'4 AA8&6 - lbqjf February 4, 1932 CONFIDENTIAL MEMO TO: FROM M. A. SMOOK PPD CHS 314 B. C. McKUSICK / -/ -< ? r /V 'sC * s' W S / MEETING WITH 3M ON C-8 (FC-143) You, I, G. L. Kennedy and R. E. Staples met with E. Lamprecht (pathologist), F. D. Griffith (toxicology manager) and W. Pearlson (regulatory manager) of 3M in Chicago, February 3. Lamprecht described two negative oral teratology studies with C-8, one in rats, one in rabbits. Griffith gave us a copy of the rat report. The rabbit report is circulating for approval and should be in official form in about two weeks. Staples described the two Haskell teratology studies in rats, one feeding and one inhalation study. Both are negative. I gave Griffith a copy of each report. Kennedy reported work on the rate of transfer of C-8 across the placenta to the fetus in pregnant rats. He also described studies to establish where C-8 concentrates in blood. Pearlson reported on blood organofluorine of some 600 employees at two plants. Most employees had levels in the 1-5 ppm range, but a few were in the low twenties. Levels were similar in a plant using C-8 and in one using two other fluorosurfactants (probably RpSt^M and a fluoroalcohol). Average levels have been slowly dropping with tighter standards and better work practices, but seem to be leveling off. An examination of liver enzyme levels confirmed earlier studies in showing no adverse health, effects related to organofluorine in the blood. EID071712 BETTER THINGS FOR BETTER LIVING . . . THROUGH CHCHISTRY 000181 UP000779 M. A. Smook - 2- February 4, 1982 We set Wednesday/ March 3, as a date to inform employees of the results of the teratology studies. I will exchange employee statements by phone with Griffith or Frank bel on March 1. During the week of March 10, Pearlson and a 3M toxi cologist will report the conclusions from the four tera tology studies of C-8 to EPA. They will also report on related work on two other fluorosurfactants. They will give EPA the reports of their two studies. I will accompany them to give EPA the reports of the two Haskell studies and to answer questions on those studies if EPA has any. Plans for the EPA visit should be ready by March 1. Staples will determine a suitable journal for publishing the teratology studies. He will prepare a paper on the Du Pont work and Lamprecht will prepare one on 3M's work. The papers will be submitted at the same time in the second quarter. BCM/ms 08/nnrunn ElDOinn 000182